Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cleave Biosciences Takes $42M Series A Round

This article was originally published in The Pink Sheet Daily

Executive Summary

Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.

You may also be interested in...

Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at for a free trial.

Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing

FDA has expressed preference for having multiple confirmatory trials in the works to support an accelerated approval application.

Proteostasis Teams Up With Elan In $50M Neurodegenerative Collaboration

Irish company will get a 24% stake in the U.S. biotech as part of an R&D collaboration centered around neurodegenerative diseases.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts